This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
New drug triggers rapid cell death in cancer models By Karen Zusi-Tran October 29, 2024 Breadcrumb Home New drug triggers rapid cell death in cancer models BRD-810 inhibits the MCL1 protein and reactivates apoptosis in tumor cells, displaying therapeutic potential in animal models. By Karen Zusi-Tran October 29, 2024 Credit: National Cancer Institute Human cells with acute myelocytic leukemia (AML) in the pericardial fluid.
Imagine being able to create an in vitro replica of a diseased organ to study the molecular mechanism underlying the illness. Now take a step further: envision testing drugs in these organoids to identify the ones that can treat disease safely and effectively without needing to run expensive clinical trials first. Further still, think about implanting these mini organs into the patient to restore lost function.
As the pharmaceutical industry continues to evolve, drug developers encounter new challenges and opportunities in their pursuit of innovation. From adapting to complex new trial designs to embracing cutting-edge technologies, staying ahead requires a deep understanding of the current landscape. In response, the PPD clinical research business of Thermo Fisher Scientific conducted its third global survey of 150 drug developers to capture a comprehensive view of these evolving trends.
Buildup of a protein called filamentous actin, or F-actin, in the brain inhibits the removal of cellular wastes, including DNA, lipids, proteins and organelles. The resulting accumulation of waste diminishes neuronal functions and contributes to cognitive decline. By tweaking a few very specific genes in the neurons of aging fruit flies, the researchers prevented F-actin buildup, maintained cellular recycling and extended the healthy lifespan of fruit flies by approximately 30%.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
The pharmaceutical industry is known for its complex regulatory environment and lengthy product development processes. One often overlooked aspect of this industry is the potential benefits of abandoned and expired patents. These patents can provide opportunities for companies to bring new products to market at a lower cost and with reduced development time.
At DrugBank, we’re dedicated to empowering pharmaceutical researchers with data that drives impactful results. Now, through our partnership with Snowflake, we’re making it even easier than ever for you to access high-quality, actionable data in a secure, and scalable environment designed to keep pace with your research needs. With this integration, we’re focused on enhancing your ability to access the data you need, when you need it.
Researchers map communities of single cells in metastatic breast cancers By Corie Lok October 30, 2024 Breadcrumb Home Researchers map communities of single cells in metastatic breast cancers The team compared different single-cell and spatial profiling methods to explore the diversity of cells in metastatic breast cancer biopsies. By Sarah C.P. Williams October 30, 2024 Credit: Cecil Fox, National Cancer Institute, National Institutes of Health Human breast cancer tissue with cancer cells (purp
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Researchers map communities of single cells in metastatic breast cancers By Corie Lok October 30, 2024 Breadcrumb Home Researchers map communities of single cells in metastatic breast cancers The team compared different single-cell and spatial profiling methods to explore the diversity of cells in metastatic breast cancer biopsies. By Sarah C.P. Williams October 30, 2024 Credit: Cecil Fox, National Cancer Institute, National Institutes of Health Human breast cancer tissue with cancer cells (purp
In recent years, advanced manufacturing has gained traction in the pharmaceutical industry, transforming how drugs are developed, produced, and delivered. It is recognized, however, that there is a learning curve across the industry and FDA that is inherent to the development of such novel technologies. To prevent this learning curve from becoming a roadblock on the path to regulatory approval, the FDA has developed several collaborative programs to support advanced manufacturing.
Autoimmune diseases and bone health conditions are not just medical challenges – they’re personal battles that millions of people fight every day. From the unpredictability of lupus flare-ups to the silent progression of osteoporosis, patients face daily struggles that can significantly impact their quality of life. Fortunately, advances in clinical research are providing hope for better treatments and outcomes.
The integration of AI in drug discovery is revolutionizing the way researchers approach the development of new treatments for various diseases. Traditional. The integration of AI in drug discovery is revolutionizing the way researchers approach the development of new treatments for various diseases. Traditional methods are often time-consuming and costly, with the process of bringing a new drug to market taking up to 15 years and costing between $1–2B.
The pharmaceutical industry relies heavily on Contract Development and Manufacturing Organizations (CDMOs) to streamline the drug development and manufacturing process. CDMOs provide a wide range of services that cater to the diverse needs of pharmaceutical companies, from early-stage development to commercial manufacturing.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Welcome to our new blog series on a REPROCELL 3D tissue engineering platform powered by Alvetex® technology. This series aims to inform and educate the research community and industry partners about the significance and benefits of cutting-edge bioengineered 3D human tissue model systems, which may be instrumental in facilitating translational research studies and accelerating the development of drugs and products.
Addressing the Talent Shortage While fears of AI-driven job displacement dominate headlines, the real crisis looming is a $8.5 trillion talent shortage projected by 2030. Much like the famous ‘invisible gorilla’ experiment, where viewers focused on counting basketball passes miss a costumed figure walking through the scene, businesses risk overlooking a crucial element: the Employee Experience (EX).
By Larry K. Houck — Eric Idle, as a body collector, immortalized the phrase, “Bring out your dead! Bring out your dead!” in the 1975 comedy classic, Monty Python and the Holy Grail. The Drug Enforcement Administration (“DEA”) would do well to update that phrase as “Bring out your meds! Bring out your meds!” to call attention to the 26th National Prescription Take Back Day.
By: Juliane Mills, Senior Director, Therapeutic Strategy Lead, Rare Disease The rise of patient-led clinical research, particularly in rare disease, represents a significant shift in the clinical trial landscape. Increasingly, patients and patient-led organizations are playing a pivotal role in shaping drug development, underscoring the importance of collaboration between patient organizations, CROs, and pharmaceutical and biotechnology companies.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Limited Evidence for Nalfmefene "In 2021, due to the widespread availability of high-potency synthetic opioids like fentanyl, the US FDA approved two high-dose naloxone products, an 8 mg IN spray (Kloxxado) and a 5 mg IM injectable (Zimhi). The only studies reported in the FDA package inserts for both products are pharmacokinetic studies in healthy volunteers, which demonstrated substantially higher naloxone plasma levels than standard doses of naloxone (0.4 mg IM vs. 8 mg IN and 2 mg IM vs. 5 m
The pharmaceutical industry has undergone significant transformations in recent years, driven by the COVID-19 pandemic and the subsequent need for rapid innovation and adaptation.
Today’s guest post comes from Angie Franks, Chief Executive Officer of Kalderos. Angie discusses how the Maximum Fair Price provision of the Inflation Reduction Act of 2022 will challenge providers, pharmacies, and manufacturers. She explains how Kalderos’ Truzo platform could reduce duplicate claims and address compliance issues. To learn more, register for Kalderos’ October 25 webinar Cracking the MFP Code: How Flexible Technology Helps You Navigate an Evolving Landscape.
Welcome to Our New Series on Auditory Disabilities in Healthcare We’re excited to introduce our new blog series that delves into the crucial yet often overlooked topic of auditory disabilities in healthcare. Our goal is to shed light on the unique challenges faced by individuals with auditory disabilities and to highlight the importance of inclusive and universal design in healthcare settings.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
By Mark A. Tobolowsky — The Rare Pediatric Disease Priority Review Voucher program has had a bit of a tumultuous history in its 12 short years of existence. Designed to incentivize the development of drugs for pediatric rare diseases where such development may not otherwise have occurred, vouchers may be granted for drugs for serious or life-threatening rare diseases where the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years.
Autoimmune diseases and bone health conditions are not just medical challenges – they’re personal battles that millions of people fight every day. From the unpredictability of lupus flare-ups to the silent progression of osteoporosis, patients face daily struggles that can significantly impact their quality of life. Fortunately, advances in clinical research are providing hope for better treatments and outcomes.
An experimental Alzheimer’s therapy from Cassava Sciences is still being tested in two Phase 3 studies, even as the company has come under regulatory scrutiny.
In the rapidly evolving landscape of biotechnology and pharmaceutical development, contract development and manufacturing organizations (CDMOs) have become essential partners for companies seeking to bring innovative medicines to market. However, navigating the complexities of these partnerships can be daunting, especially for smaller biotech companies.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Researchers have used artificial intelligence to design thousands of new DNA switches that can precisely control the expression of a gene in different cell types. Their new approach opens the possibility of controlling when and where genes are expressed in the body, for the benefit of human health and medical research, in ways never before possible.
Shoptalk held its first ever Fall conference in Chicago this past week and our very own Justin Racine, Principal of Unified Commerce, was present to take it all in. This year’s theme was 007, so Justin was on a reconnaissance mission to gain as much information on retail and commerce trends as possible. Here’s a debrief on his sources and the intel he was able to gather from them during his time at the show.
FRIDAY, Oct. 25, 2024 -- Some Americans should get more than one shot of the updated COVID vaccines because their age or certain health conditions make them more vulnerable to severe infections, U.S. health officials advised this week.Six months.
The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.
Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such results are just the start.
Comamonadacae is a family of bacteria often found growing on plastics in water. New study finds a bacterium in this family can break down the plastic for food. Researchers also identified the enzyme the bacterium use to degrade plastic. The discovery opens new possibilities for developing bacteria-based engineering solutions to help clean up difficult-to-remove plastic waste.
A new study reveals how the duplication of the salivary amylase gene may not only have helped shape human adaptation to starchy foods, but may have occurred as far back as more than 800,000 years ago, long before the advent of farming.
According to new research, men and women rely on different biological systems for pain relief, which could help explain why our most powerful pain medications are often less effective in women.
Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content